Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.
All Keywords
【저자키워드】 SARS-CoV-2, RNA vaccines, breath, 【초록키워드】 Efficacy, Vaccine, BNT162b2 vaccine, COVID-19 vaccine, clinical trial, Immunity, neutralization, virus, BNT162b2, D614G mutation, D614G, SARS-CoV-2 neutralization, sequence, candidate, circulating, human sera, rhesus, accumulated mutations, dominant, reduced, question, raising, 【제목키워드】 Mutation, SARS-CoV-2 D614G,
【저자키워드】 SARS-CoV-2, RNA vaccines, breath, 【초록키워드】 Efficacy, Vaccine, BNT162b2 vaccine, COVID-19 vaccine, clinical trial, Immunity, neutralization, virus, BNT162b2, D614G mutation, D614G, SARS-CoV-2 neutralization, sequence, candidate, circulating, human sera, rhesus, accumulated mutations, dominant, reduced, question, raising, 【제목키워드】 Mutation, SARS-CoV-2 D614G,
초기 COVID-19 백신 후보는 SARS-CoV-2의 원래 시퀀스를 기반으로 했습니다. 그러나 바이러스는 이후 돌연변이를 축적했으며 그 중 스파이크 D614G가 바이러스 순환에 우세해 백신 유도 면역에서 바이러스가 탈출할 가능성에 대한 의문이 제기되고 있다. 여기에서 우리는 D614G 돌연변이가 BNT162b2 백신 유도 마우스, 붉은털 원숭이 및 인간 혈청에 의한 SARS-CoV-2 중화를 완만하게 감소시켰으며, 이는 임상 시험에서 관찰된 95% 백신 효능과 일치한다고 보고합니다.